PharmaJet, a commercial-stage global leader in needle-free injection systems, has announced the expansion of its manufacturing portfolio with the development of a suite of proprietary, needle-free self-injector pens. These subcutaneous (SC) injectors are currently in early testing and are aimed at the chronic disease and metabolic peptide self-injection markets.

Self-injectable drug delivery has transformed patient care by enabling treatment at home, but challenges such as needle aversion and injection site pain often affect compliance. PharmaJet’s needle-free injector pens are designed to improve the user experience by reducing administration anxiety and discomfort, while simplifying the injection process—particularly for patients with mobility limitations. The company’s reusable design also offers an eco-friendly advantage over disposable devices that contribute to significant medical waste.

PharmaJet’s upcoming range of single-use and reusable needle-free injectors will enable precise, self-administered delivery of pharmaceuticals at home. The devices are being developed for needle-free subcutaneous delivery of a broad range of drugs, including metabolic peptides, hormones, small molecules, and antibodies.

PharmaJet already has a proven track record in needle-free vaccination, with over 12 million doses administered worldwide using its Tropis intradermal system. Research has shown Tropis is preferred by more than 95% of caregivers, with 68% reporting reduced pain and 69% reduced soreness compared with traditional needles. Additionally, use of Tropis has demonstrated improved compliance rates in routine immunisation programmes, suggesting that similar benefits may extend to PharmaJet’s new needle-free pen injectors.

“Our entry into the pen injector market with PharmaJet’s needle-free self-injector pens marks an important step forward,” said Wouter Latour, President and CEO of PharmaJet. “These devices are designed to offer a superior user experience across a wide range of patients, incorporating smart e-technology to track dosing and support compliance. We plan to collaborate with industry partners in the rapidly growing metabolic peptide and other therapeutic segments that rely on frequent injections.”

PharmaJet’s Precision Delivery Systems are known for improving vaccine effectiveness, enhancing patient and caregiver experience, and providing a proven commercial pathway. The company’s Stratis System has US FDA 510(k) clearance, CE Mark, and WHO PQS certification for intramuscular and subcutaneous delivery. The Tropis ID system also holds CE Mark and WHO PQS certification for intradermal use and is widely used in global immunisation programmes.